

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.  
Form NT 10-K  
March 30, 2012

**UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 12b-25**

OMB APPROVAL  
OMB Number: 3235-0058  
Expires: April 30, 2012  
Estimated average burden hours  
per response . . . . . 2.50

SEC FILE NUMBER  
333-147560  
CUSIP NUMBER  
883378 10 1

**NOTIFICATION OF LATE FILING**

*(Check one):*

. Form 10-K    . Form 20-F    . Form 11-K    . Form 10-Q    . Form 10-D    . Form N-SAR    . Form  
NCSR

For Period Ended: December 31, 2011

- . Transition Report on Form 10-K
- . Transition Report on Form 20-F
- . Transition Report on Form 10-Q
- . Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I REGISTRANT INFORMATION**

**THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.**

Full Name of Registrant

**4093 Oceanside Boulevard, Ste. B**

Address of Principal Executive Office (*Street and Number*)

**Oceanside, CA 92053**

(*City, State and Zip Code*)

**PART II RULES 12b-25(b)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- X (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.



**PART III NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant is unable to file, without unreasonable effort and expense, its Form 10-K Report for the period ended December 31, 2011 because its auditors have not yet had an opportunity to complete their review of the financial statements.

The Registrant's auditors are finalizing the financial statements and it is anticipated that the Form 10-K Annual Report, along with the financial statements, will be filed on or before prescribed due date of the Registrant's Form 10-K.

**PART IV OTHER INFORMATION**

- (1) Name and telephone number of person to contact in regard to this notification

**Timothy G. Dixon**

(Name)

**(760) 295-7208**

(Area Code and Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?

Yes  . No  .

If answer is no, identify report(s).

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes  . No  .

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 30, 2012

By: /s/ Timothy G. Dixon  
Timothy G. Dixon  
President and Director